OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) insider Gregory A. Odle sold 5,359 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $133,224.74. Following the completion of the sale, the insider now owns 148,788 shares in the company, valued at $3,698,869.68. This represents a 3.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
OrthoPediatrics Stock Performance
Shares of OrthoPediatrics stock traded up $0.46 on Tuesday, hitting $25.42. 138,044 shares of the company’s stock were exchanged, compared to its average volume of 162,840. The company has a 50-day simple moving average of $24.74 and a 200-day simple moving average of $25.62. The stock has a market capitalization of $617.38 million, a PE ratio of -20.67 and a beta of 1.22. OrthoPediatrics Corp. has a 1 year low of $21.02 and a 1 year high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The business had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter last year, the company posted ($0.23) EPS. As a group, equities analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current year.
Institutional Trading of OrthoPediatrics
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the stock. Truist Financial dropped their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC restated a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, March 5th. Finally, Stifel Nicolaus dropped their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th.
About OrthoPediatrics
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Further Reading
- Five stocks we like better than OrthoPediatrics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Must-Own Stocks to Build Wealth This Decade
- Investing in the High PE Growth Stocks
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.